Avadel Pharmaceuticals plc (AVDL)
AVDL Stock Price Chart
Explore Avadel Pharmaceuticals plc interactive price chart. Choose custom timeframes to analyze AVDL price movements and trends.
AVDL Company Profile
Discover essential business fundamentals and corporate details for Avadel Pharmaceuticals plc (AVDL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
7 Jun 1996
Employees
188.00
Website
https://www.avadel.comCEO
Gregory J. Divis Jr.
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
AVDL Financial Timeline
Browse a chronological timeline of Avadel Pharmaceuticals plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 2 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is $0.08.
Earnings released on 7 Aug 2025
EPS came in at $0.10 surpassing the estimated $0.02 by +400.00%, while revenue for the quarter reached $68.13M , missing expectations by -7.57%.
Earnings released on 7 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $52.51M , missing expectations by -9.79%.
Earnings released on 3 Mar 2025
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $50.41M , missing expectations by -4.07%.
Earnings released on 12 Nov 2024
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $50.03M , missing expectations by -5.07%.
Earnings released on 8 Aug 2024
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $41.50M , missing expectations by -13.98%.
Earnings released on 8 May 2024
EPS came in at -$0.30 falling short of the estimated -$0.25 by -20.00%, while revenue for the quarter reached $27.18M , missing expectations by -27.68%.
Earnings released on 4 Mar 2024
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%, while revenue for the quarter reached $19.45M , missing expectations by -48.24%.
Earnings released on 8 Nov 2023
EPS came in at -$0.41 falling short of the estimated -$0.35 by -17.14%, while revenue for the quarter reached $7.01M , missing expectations by -55.58%.
Earnings released on 9 Aug 2023
EPS came in at -$0.70 falling short of the estimated -$0.39 by -79.49%, while revenue for the quarter reached $1.50M , beating expectations by +137.46%.
Earnings released on 4 May 2023
EPS came in at -$0.48 falling short of the estimated -$0.37 by -29.73%.
Earnings released on 30 Mar 2023
EPS came in at -$0.44 falling short of the estimated -$0.30 by -46.67%.
Earnings released on 9 Nov 2022
EPS came in at -$0.33 falling short of the estimated -$0.22 by -50.00%.
Earnings released on 9 Aug 2022
EPS came in at -$0.50 falling short of the estimated -$0.41 by -21.95%.
Earnings released on 9 May 2022
EPS came in at -$0.45 falling short of the estimated -$0.44 by -2.27%.
Earnings released on 17 Mar 2022
EPS came in at -$0.38 surpassing the estimated -$0.42 by +9.52%.
Earnings released on 8 Nov 2021
EPS came in at -$0.38 matching the estimated -$0.38.
Earnings released on 9 Aug 2021
EPS came in at -$0.33 falling short of the estimated -$0.31 by -6.45%.
Earnings released on 10 May 2021
EPS came in at -$0.23 surpassing the estimated -$0.32 by +28.13%.
Earnings released on 9 Mar 2021
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%, while revenue for the quarter reached $0.00 .
Earnings released on 9 Nov 2020
EPS came in at -$0.20 surpassing the estimated -$0.26 by +23.08%, while revenue for the quarter reached $14.23M .
AVDL Stock Performance
Access detailed AVDL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.